Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...
Read More
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....
Read More
It’s a new year, but sadly Congress is still pursuing flawed price setting policies

As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...
Read More
Post-approval research save lives. Why is Congress trying disincentivize it?

While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...
Read More
A price control by any other name would still put patients at risk and threaten innovation

Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...
Read More
New data show insurers and PBMs increase barriers to care

New data show insurers and middlemen known as pharmacy benefit managers (PBMs) are making it harder for patients to get the medicines they need.
Read More
Making medicines more affordable: Modernizing Medicare

Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...
Read More
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...
Read More
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...
Read More
Recent polling misrepresents public support for Medicare “negotiation”

Proponents of government price setting often misrepresent voters’ opinions on support for allowing the federal government to “negotiate” drug prices. This includes recent polling from advocacy firms...
Read More